Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
PAR:SIGHT
Price:
0.0761
EUR
-2.44%
Market Closed
Market Cap:
€14.5m
Income Statement
Earnings Waterfall
Gensight Biologics SA
Gensight Biologics SA
Income Statement
Gensight Biologics SA
Gensight Biologics SA
Currency: EUR
| Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
0
|
0
|
0
|
1
|
2
|
2
|
2
|
1
|
3
|
1
|
3
|
3
|
2
|
3
|
|
| Revenue |
0
N/A
|
0
N/A
|
1
N/A
|
1
+100%
|
4
+214%
|
9
+111%
|
5
-43%
|
8
+58%
|
3
-69%
|
4
+60%
|
1
-69%
|
2
+86%
|
2
-36%
|
0
-87%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(33)
|
(39)
|
(31)
|
(28)
|
(29)
|
(27)
|
(33)
|
(49)
|
(30)
|
(49)
|
(31)
|
(39)
|
(17)
|
(15)
|
|
| Selling, General & Administrative |
(8)
|
(8)
|
(6)
|
(7)
|
(9)
|
(10)
|
(13)
|
(19)
|
(13)
|
(20)
|
(13)
|
(16)
|
(6)
|
(6)
|
|
| Research & Development |
(29)
|
(35)
|
(28)
|
(24)
|
(22)
|
(18)
|
(23)
|
(32)
|
(19)
|
(31)
|
(17)
|
(22)
|
(11)
|
(10)
|
|
| Depreciation & Amortization |
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(4)
|
(1)
|
(1)
|
|
| Other Operating Expenses |
4
|
5
|
4
|
4
|
3
|
2
|
2
|
4
|
2
|
3
|
2
|
2
|
1
|
1
|
|
| Operating Income |
(33)
N/A
|
(39)
-18%
|
(30)
+22%
|
(27)
+12%
|
(25)
+7%
|
(18)
+28%
|
(28)
-56%
|
(40)
-43%
|
(28)
+31%
|
(45)
-61%
|
(30)
+34%
|
(37)
-26%
|
(16)
+58%
|
(15)
+4%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(1)
|
(1)
|
(9)
|
(10)
|
(0)
|
(0)
|
1
|
6
|
3
|
5
|
2
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(33)
N/A
|
(39)
-17%
|
(31)
+21%
|
(28)
+9%
|
(34)
-21%
|
(28)
+17%
|
(29)
-1%
|
(39)
-37%
|
(28)
+30%
|
(40)
-43%
|
(26)
+34%
|
(32)
-21%
|
(14)
+56%
|
(15)
-8%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
0
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(33)
|
(39)
|
(31)
|
(28)
|
(34)
|
(28)
|
(29)
|
(39)
|
(28)
|
(40)
|
(26)
|
(32)
|
(14)
|
(15)
|
|
| Net Income (Common) |
(33)
N/A
|
(39)
-17%
|
(31)
+21%
|
(28)
+9%
|
(34)
-21%
|
(28)
+17%
|
(29)
-1%
|
(39)
-37%
|
(28)
+30%
|
(40)
-43%
|
(26)
+34%
|
(32)
-21%
|
(14)
+56%
|
(15)
-8%
|
|
| EPS (Diluted) |
-1.37
N/A
|
-1.41
-3%
|
-1.09
+23%
|
-0.85
+22%
|
-0.97
-14%
|
-0.64
+34%
|
-0.63
+2%
|
-0.86
-37%
|
-0.6
+30%
|
-0.86
-43%
|
-0.54
+37%
|
-0.38
+30%
|
-0.15
+61%
|
-0.13
+13%
|
|
Switch to:
Switch to:
See Also
Discover More
